BioVie Targets Brain Inflammation in Alzheimer's and Long COVID Push

CARSON CITY, Nev. – February 12, 2026 – BioVie Inc., a clinical-stage biopharmaceutical company, has signaled its growing ambition in the neurology space, announcing that early findings for its lead drug candidate, bezisterim, will be presented at a major psychiatric conference. The company confirmed that two abstracts detailing the drug's application in Alzheimer’s Disease and Long COVID have been accepted for the 2026 American College of Psychiatrists (ACP) annual meeting later this month.

The announcement places a spotlight on bezisterim (also known as NE3107), an oral medication designed to tackle the complex interplay of inflammation and metabolic dysfunction in the brain. For patient communities grappling with the devastating effects of Alzheimer's and the persistent, debilitating symptoms of Long COVID, the news represents an early but potentially significant development in the search for effective treatments where few currently exist.

A New Front Against Neuroinflammation

At the heart of BioVie's strategy is a scientific approach that diverges from many mainstream efforts, particularly in Alzheimer's research. For decades, the primary focus has been on clearing amyloid plaques, the sticky protein clumps that are a hallmark of the disease. While recent drugs like Leqembi have shown modest success with this method, they come with challenges, including intravenous administration and risks of brain swelling and bleeding.

Bezisterim targets a different, albeit related, culprit: chronic neuroinflammation. It is designed to modulate key inflammatory pathways—including NFκB and TNF-α—that are increasingly understood to be major drivers of neuronal damage in neurodegenerative diseases. By calming this inflammatory storm, the drug aims to protect brain cells and restore function.

"The scientific community is increasingly recognizing that inflammation is not just a byproduct of diseases like Alzheimer's, but a central pillar of the pathology," noted a neurologist not affiliated with the company. "An approach that can safely and effectively reduce neuroinflammation without shutting down the entire immune system would be a paradigm shift."

Bezisterim's potential advantages are notable. As an oral small molecule, it can be taken as a pill, a significant quality-of-life improvement over hospital-based infusions. It is also designed to cross the blood-brain barrier, a critical hurdle for any drug targeting neurological conditions. Furthermore, the company reports it can improve the brain's insulin sensitivity, addressing the metabolic component of neurodegeneration often referred to as "Type 3 diabetes."

For Long COVID, a condition characterized by persistent brain fog, fatigue, and other neurological symptoms, this anti-inflammatory mechanism is particularly relevant. The prevailing theory is that lingering fragments of the SARS-CoV-2 virus trigger a chronic inflammatory response. A drug like bezisterim, which modulates the very pathways believed to be activated by these fragments, could theoretically disrupt the cycle that perpetuates Long COVID's most debilitating symptoms.

A Broad Strategy for High-Stakes Diseases

The upcoming presentations at the ACP meeting are part of a broader, ambitious strategy for BioVie. Rather than focusing on a single indication, the company is leveraging bezisterim as a platform drug, testing its efficacy across a spectrum of neurological disorders that share common inflammatory underpinnings. This high-risk, high-reward approach allows the small-cap biotech to pursue some of the largest and most challenging markets in medicine.

Beyond Alzheimer's and Long COVID, bezisterim has already been studied in Parkinson's disease. A completed Phase 2 trial showed that patients taking the drug alongside standard levodopa therapy experienced improved motor control. Now, a new study, SUNRISE-PD, is evaluating bezisterim as a standalone treatment for early-stage Parkinson's patients, with topline results anticipated in mid-2026.

Simultaneously, the ADDRESS-LC trial is actively enrolling up to 200 patients to determine if bezisterim can alleviate the brain fog and fatigue associated with Long COVID. With no FDA-approved treatments for this condition, a positive outcome from this trial, also expected in mid-2026, could position BioVie as a leader in a vast and underserved market.

This multi-pronged clinical development plan diversifies risk and maximizes the potential of a single promising asset. It also suggests a deep confidence in the drug's core mechanism. While the company's portfolio also includes BIV201, a treatment for advanced liver disease with FDA Fast Track designation, all eyes are currently on bezisterim and the series of clinical milestones expected over the next year.

The Patient Perspective: A Glimmer of Hope

For the millions of people affected by these conditions, scientific mechanisms and corporate strategies are secondary to a single, urgent question: will it help? Alzheimer's disease currently affects over six million Americans, a number projected to more than double by 2060, leaving a trail of cognitive decline and family heartbreak. In this landscape, any novel approach that offers a chance to slow the disease, especially one with a potentially better safety and convenience profile, is a source of profound hope.

The Long COVID community faces a different but equally daunting reality. An estimated 17 million adults in the U.S. have experienced the condition, with millions currently suffering from symptoms that can make work, school, and daily life impossible. They are navigating a medical system that is still learning about their illness, with no approved cures and a frustrating process of trial-and-error symptom management. The prospect of a targeted therapy aimed at the root inflammatory cause offers a tangible possibility of relief.

The poster presentations at the ACP meeting, while representing early-stage data, are a crucial step in the long road of drug development. They allow the underlying science to be vetted by the broader medical community and signal that the research is moving forward.

Navigating the Path to Approval

Despite the promise, the path ahead for BioVie and bezisterim is fraught with the standard challenges of pharmaceutical development. Clinical trials are notoriously unpredictable, and neurology is a field littered with high-profile failures. The upcoming data readouts in mid-2026 for both the Parkinson's and Long COVID trials will be critical inflection points, offering the first large-scale human data on the drug's efficacy in these populations.

Positive results could transform BioVie's prospects, attracting partners, investment, and a clear path toward regulatory submission. Inconclusive or negative results would represent a significant setback. The abstracts presented at the ACP meeting will offer an early glimpse into the data and methodology that underpin the company's confidence. For now, the scientific and patient communities will be watching closely, hopeful that this novel approach to taming inflammation in the brain will translate from a promising theory into a much-needed therapy.